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Abstract
Background: Most HIV-infected persons are cytomegalovirus (CMV) seropositive and retain latent virus that can be
reactivated by immune activation. Their T cell populations express markers reflecting a late stage of differentiation,
but the contributions of HIV and CMV to this profile are unclear. We investigated the immunological “footprint” of
CMV in HIV patients who had a history of extreme immunodeficiency but were now stable on antiretroviral therapy
(ART).
Results: Twenty CMV seropositive HIV patients >50 years old with nadir CD4 T-cell counts <200 cells/μl were
studied after >12 years on ART. 16 CMV seropositive and 9 CMV seronegative healthy controls were included. CMV
antibody titres were higher in HIV patients than controls (P < 0.001-0.003). Levels of soluble B-cell activating factor
(sBAFF) were elevated in patients (P = 0.002) and correlated with levels of CMV antibodies (P = 0.03-0.002), with no
clear relationship in controls. CD8 T-cell IFNγ responses to the IE1 peptide (VLE) remained elevated in HIV patients
(P = 0.005). The CD57+CD45RA+CD27− phenotype of CD8 T-cells correlated with age (r = 0.60, P = 0.006), antibodies
against CMV IE1 protein (r = 0.44, P = 0.06) and CD4 T-cell IFNγ response to CMV lysate (r = 0.45, P = 0.05).
Conclusions: Humoral and T-cell responses to CMV remained elevated in HIV patients after >12 years on ART. Age
and presence of CMV disease influenced CD8 T-cell phenotypes. Elevated levels of sBAFF may be a consequence of
HIV disease and contribute to high titres of CMV antibody.
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Background
Cytomegalovirus (CMV) infections may be asymptom-
atic or cause mild symptoms in immunocompetent
hosts, but can cause morbidity and mortality in human
immunodeficiency virus -1 (HIV) patients. CMV end-
organ disease is common in patients with low CD4-T-
cell counts, but long term consequences are less clear.
At any time, immune activation may promote the reacti-
vation of CMV leading to the re-stimulation of CMV-
specific T-cells [1]. This creates T-cell populations
enriched with differentiated, apoptosis-resistant memory
T cells with limited proliferative capabilities, and leaves
an immune system with limited capacity to recognize
novel antigens [2]. In the elderly people not infected
with HIV, CMV infection has been linked with acceler-
ated immune ageing and/or immunosenescence [3–5],
with increased risk for mortality and age-related morbid-
ities [2].
It is reasonable to hypothesize that CMV and other
coinfections may contribute to the “accelerated ageing”
syndrome observed in HIV-infected individuals [1, 6].
CMV coinfection has been associated with an increased
risk of severe non-acquired immune deficiency syn-
drome (AIDS)-defining events in HIV-infected patients
[7]. Untreated HIV infection and chronological ageing
are similarly associated with many T cell abnormalities
[8, 9]. This includes low CD4/CD8 ratios, low naïve/
memory T cell ratios, reduced T cell repertoire, and an
expansion of CD57+ T cells. CD57 expression can be
used to monitor proliferative history, poor proliferative
capacity [9], replicative senescence and antigen-induced
apoptotic death [10]. Memory T-cells that have undergone
multiple rounds of restimulation can also be characterized
phenotypically by re-expression of CD45RA [11] and the
absence of CD27 [12]. Persistent viral infections, inflam-
matory syndromes and ageing induce the accumulation of
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highly differentiated memory T cells re-expressing
CD45RA [13]. In HIV infected children and CMV-
seropositive healthy children [14], the frequency of
CD45RA+CD27− phenotype on CD8 T cells correlated
with previous CMV infection as measured by serum im-
munoglobulin G (IgG) levels against CMV. Here we ad-
dress which CD4 and CD8 T cell markers best define the
T-cell phenotype associated with a high burden of CMV
in older HIV patients stable on combination antiretroviral
therapy (ART).
HIV-seronegative, CMV-seropositive individuals who
control CMV replication have very high frequencies
of CMV-specific CD8 T-cells able to respond to mul-
tiple CMV proteins [15]. Proportions of CMV reactive
CD8 T-cells rise rapidly with age in HIV infected pa-
tients [16]. The CMV proteins pp65, glycoprotein B
(gB) and Immediate Early-1 (IE1) [17] are targets of
the CD8 T-cell response against CMV. The peptides
NLVPMVATV [“NLV” from CMV pp65] and
VLEETSVML [“VLE” from CMV IE1] evoke easily
measurable CD8-T-cell responses in healthy CMV-
seropositive individuals carrying human leucocyte
antigen (HLA)-A*02 [18]. Stone et al. showed that re-
sponses to VLE were elevated in previously immuno-
deficient HIV patients stable on ART when compared
to controls [19]. IE1 is expressed early during CMV
replication so these cells may be important for pro-
tection against CMV reactivation from latency.
Levels of monocyte and B-cell activation are ele-
vated in untreated HIV patients and may remain high
on ART [20]. Markers of monocyte activation and
tumour necrosis factor (TNF) activity include soluble
TNF receptor 1 (sTNFR1) [21] and soluble CD14
(sCD14) [22]. B cell activation can be gauged through
levels of total IgG and soluble B-cell activating factor
(sBAFF) [23]. BAFF is a novel member of the TNF
ligand family and plays an important role in B
lymphocyte maturation and survival. BAFF is involved
in the pathogenesis of several autoimmune disorders
[24] and with risk of long-term kidney graft dysfunc-
tion [25].
With the increased availability of ART worldwide,
large numbers of patients begin ART with advanced
HIV disease and live for many years. This present
study investigates T-cell changes as a “footprint” of
CMV in a unique cohort of older HIV patients who
began ART with advanced immunodeficiency more
than twelve years previously and have maintained viral
suppression for more than a year. We measured levels
of antibodies to CMV lysate, CMV IE1 and CMV gB,
using extensive titrations to ensure quantitation in the
high range. As titres of all three antibodies were ele-
vated in the HIV patients, we sought explanations for
the increase. This included the assessment of sTNFR1,
sCD14, total IgG and sBAFF, as well as host interferon
gamma (IFNγ) responses of CD4 and CD8 T-cells to
CMV proteins.
Results
CMV lysate, CMV gB and CMV IE1 antibody titres are
higher in HIV patients than healthy controls and more
tightly correlated
The study focuses on the long term outcome for CMV
seropositive HIV patients stable on ART. HIV patients
presented with a median nadir CD4 T-cell count of 78
cells/μL (range: 0–195). Eleven of the 20 HIV patients
and 9 out of 16 CMV seropositive (CMV+) controls car-
ried the HLA-A*02 allele, but no CMV seronegative
(CMV-) controls were carriers. HIV patients had been
on ART for more than 12 years [174 (159–189) months]
with a median CD4 T-cell count of 691 cells/μL (range:
372–1848) at time of testing.
HIV patients and CMV+ controls were similar in
age, but CMV- controls were slightly younger (Table 1).
Levels of antibodies reactive with CMV lysate, CMV gB
and CMV IE1 were higher in HIV patients than CMV+
controls (Table 1). In HIV patients, levels of antibodies
reactive with different CMV antigens were tightly cor-
related (lysate vs gB, r = 0.81, P < 0.0001; lysate vs IE1,
r = 0.70, P = 0.0005; gB vs IE1, r = 0.57, P = 0.009). In
CMV+ controls, similar trends were evident (lysate vs
gB, r = 0.57, P = 0.02; lysate vs IE1, r = 0.52, P = 0.04) al-
though CMV gB and CMV IE1 did not differ (r = 0.17,
P = 0.53).
High CMV antibody levels in HIV patients may reflect
increased exposure to CMV antigens before they began
ART, but could also indicate persistent B-cell activation.
Hence, we assessed levels of sBAFF and total IgG to
examine whether antibody levels reactive with CMV
reflect polyclonal B-cell activation.
B-cell activation (sBAFF and IgG), but not monocyte
activation (sCD14 and sTNFR1), may contribute to high
CMV antibody titres in HIV patients
HIV patients had higher levels of sBAFF than CMV+ con-
trols (Table 1). There was a direct relationship between
CMV antibodies and sBAFF in patients [CMV lysate (r =
0.72, P = 0.002), CMV gB (r = 0.70, P = 0.003), CMV IE1 (r
= 0.54, P = 0.03)]. However in CMV+ controls, a weak in-
verse relationship was observed between levels of sBAFF
and CMV lysate (r = −0.47, P = 0.08) and CMV IE1 (r =
−0.51, P = 0.06)]. In HIV patients, sBAFF levels correlated
with levels of total IgG (r = 0.70, P = 0.003), but this was
not seen in CMV+ controls (r = −0.53, P = 0.04).
Levels of total IgG in HIV patients correlated with
antibodies to CMV gB (r = 0.65, P = 0.002) and CMV
lysate (r = 0.40, P = 0.08) however these observations were
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not evident in CMV+ controls (r = 0.09 to 0.30, P = 0.26
to 0.74).
Levels of sCD14 and sTNFR1 were similar in all groups
(Table 1). In CMV+ controls, sCD14 levels correlated
inversely with CMV antibodies (CMV lysate, r = −0.50,
P = 0.05; CMV gB, r = −0.51, P = 0.05; CMV IE1, r = −0.49,
P = 0.06), whilst these parameters were unrelated in pa-
tients (r = 0.04 to 0.35, P = 0.13 to 0.86). sTNFR1 levels
did not correlate with antibodies to CMV antigens in any
group.
IFNγ responses to the CMV IE1 peptide (VLE) remain
elevated in HIV patients
IFNγ responses were assessed by enzyme linked im-
munosorbent spot assay (ELISpot) in peripheral blood
mononuclear cells (PBMC) stimulated with whole
CMV lysate (mediated by CD4 T-cells), CMV pp65
peptide pool (mediated by CD4 and CD8 T-cells),
CMV, EBV and influenza (CEF) control peptide pool
(mediated by CD8 T-cells), and HLA-A*02 restricted
CMV peptides (VLE and NLV; mediated by CD8 T-
cells) [26].
HIV patients had more CD4 and CD8 T-cells producing
IFNγ in response to CMV pp65 peptide pool (P = 0.005,
Table 1) and more CD8 T-cells producing IFNγ in
response to VLE peptide (P = 0.005) than CMV+ controls.
However, numbers of CD4 T-cells responding to CMV
lysate were similar in patients and CMV+ controls
(Table 1) and responses to the CEF peptide pool were only
marginally lower in CMV+ controls (Table 1). This had
been described in patients from our clinic tested after
4 years on ART and 6 months of complete viral suppres-
sion [19]. As expected, CMV- controls had low/undetect-
able IFNγ responses to CMV lysate (Table 1), CMV pp65
peptide pool (Table 1) or even CEF control peptide pool
(P = 0.001) (Table 1).
Table 1 HIV patients stable on ART retain elevated humoral and cellular responses to CMV and advanced T-cell senescence
HIV patients CMV + Controls CMV- Controls A vs B A vs C B vs C
A B C Pb Pb Pb
n 20 16 9
Male:Female 19:1 14:2 9:0
Age (years) 62.5 (50–73)a 60 (50–74)a 55(52–69)a 0.19 0.03 0.12
Levels in Plasma
CMV lysate antibody AU/L 94 (23–995) 20 (6–83) 0.8 (0.5–1.1) <0.0001 <0.0001 <0.0001
CMV gB antibody AU/L 127 (27–400) 45 (2–88) 2 (0.6–3.3) <0.0001 <0.0001 <0.0001
CMV IE-1 antibody AU/L 49 (8–1098) 9 (2–180) 2.6 (1.9–10) <0.0001 <0.0001 0.003
sCD14 ng/mL 22 (7.7–48) 18 (8.3–39) 22 (11–31) 0.09 0.23 0.68
sTNFR1 pg/mL 15 (9.1–25) 15 (12–27) 17 (10–21) 0.68 0.83 0.72
Total IgG mg/mL 12 (3–22) 12 (5–20) 9.4 (6.5–15) 0.46 0.16 0.14
sBAFF ng/mL 740 (376–1401) 519 (274–786) 319 (318–471) 0.002 0.0003 0.06
IFNγ spots per 2 × 106 cells
CMV lysate 227 (16–700) 157 (13–617) 0 (0–0.5) 0.16 <0.0001 <0.0001
CMV pp65 445 (14–1591) 138 (18–645) 0 (0–2) 0.005 <0.0001 <0.0001
CEF control peptide pool 516 (2–1500) 337 (20–584) 4 (0–404) 0.07 0.001 0.0015
NLV peptide 498 (56–1363)c 214 (13–651)d na 0.06 na na
VLE peptide 420 (14–2000)c 25 (7–561)d na 0.005 na na
T cell subset [as % of]
CD4+ T cells [lymphocytes] 43 (24–77) 69 (52–84) 69 (52–80) <0.0001 0.0009 0.93
CD57+ [CD4] 11 (2–75) 8 (2–26) 4.5 (1.7–7.4) 0.11 0.001 0.03
CD57+CD45RA+CD27− [CD4] 1.9 (0–57) 0.44 (0.06–14) 0.02 (0.005–0.16) 0.06 0.0002 0.0001
CD8+ T cells [lymphocytes] 48 (16–71) 22 (7–43) 21 (15–44) 0.0001 0.002 0.97
CD57+ [CD8] 47 (17–67) 40 (6.4–69) 28 (10–68) 0.08 0.04 0.51
CD57+CD45RA+CD27− [CD8] 19 (4.2–53) 26 (4–49) 8 (2–19) 0.61 0.03 0.0001
na = Not applicable as none of the CMV-seronegative healthy controls carried the HLA-A*02 allele
aMedian (range)
bMann–Whitney, P ≤ 0.05 (bold), P > 0.05-0.1 (italics)
cHLA-A*02 allele restricted thus HIV+ patients n = 11
dCMV+ controls n = 9
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In HIV patients, expression of CD57+CD45RA+CD27− on
CD8 T-cells correlated with age, CMV IE1 and CD4 T-cell
IFNγ responses to CMV lysate
Proportions of CD8 T-cells in HIV patients were higher
than in controls (Table 1), but the CD57+ or CD57
+CD45RA+CD27− phenotypes of CD8 T-cells were
equally common in HIV patients and CMV+ controls
(Table 1). However CMV- controls had few CD8 T-cells
expressing CD57+CD45RA+CD27−, so the accumulation
of these cells is driven by CMV.
In HIV patients, proportions of CD8 T-cells with highly
differentiated phenotypes (CD57+ or CD57+CD45RA+
CD27−) correlated with age (r = 0.67, P = 0.001; r =
0.60, P = 0.006, resp), antibodies reactive with CMV
IE1 (r = 0.44, P = 0.06; r = 0.41, P = 0.07) and IFNγ re-
sponses to CMV lysate (r = 0.45, P = 0.05; r = 0.42, P =
0.07). Expression of CD57+ on CD8 T-cells was also
correlated with IFNγ responses to the CMV IE1 VLE
peptide (n = 9; r = 0.60, P = 0.05) and age (r = 0.67, P =
0.001). CMV+ controls did not show equivalent
correlations.
HIV patients retained lower proportions of CD4 T-cells
than CMV+ or CMV- controls (Table 1). Proportions of
CD4 T-cells with the phenotype CD57+CD45RA+CD27−
were marginally higher in HIV patients than in CMV+
controls (Table 1). CMV+ controls had more CD57+ or
CD57+CD45RA+CD27− CD4 T-cells than CMV- controls
so again CMV is the driving force for CD4 T-cell differenti-
ation (Table 1). Accordingly in patients, CD57 expression
on CD4 T-cells correlated weakly with antibody and IFNγ
responses to CMV lysate (r = 0.41, P = 0.07; r = 0.39,
P = 0.09).
Discussion
CMV seropositivity has been placed in an “immune risk
profile” associated with mortality in longitudinal studies
of people over 85 years old [3, 5]. Here, we describe
investigations of a unique cohort of CMV seropositive
HIV patients over 50 years of age who began ART with
advanced immune deficiency over 12 years earlier and
maintained undetectable plasma HIV RNA for more
than a year. Their levels of antibodies reactive with
CMV lysate, gB and IE1 remained elevated despite the
long period on effective ART.
Elevated sBAFF levels have been associated with auto-
immune diseases [27], graft versus host disease [28], and
complications of kidney transplantation [29]. In CMV-
deoxyribonucleic acid (DNA) positive renal transplant
patients, sBAFF levels were higher than in CMV-DNA
negative recipients, with positive correlations between
CMV-DNA levels, total IgG and sBAFF [30]. Here, levels
of sBAFF and total IgG correlated with antibodies react-
ive with CMV lysate, CMV gB and CMV IE1 in HIV pa-
tients. This suggests that B-cell activation is a feature of
HIV disease and contributes to elevated titres of CMV
antibodies. Although we found no associations between
CMV antibodies and levels of sTNFR1 or sCD14, this
may be apparent in extended studies that include HIV
+CMV- patients and assess CMV-DNA. HIV+CMV- pa-
tients are rare so collaborative studies will be needed.
HIV+CMV+ patients had higher frequencies of CD8
T-cells specific for the CMV IE1 VLE peptide than CMV
+ healthy controls, whilst frequencies of CD8 T-cells
specific for the CMV pp65 NLV peptide were less clearly
elevated, as expected [19]. IE1 proteins are expressed be-
fore pp65 during CMV reactivation, thus HIV patients
on ART may experience CMV reactivation more fre-
quently than controls. IFNγ responses to CMV pp65
peptide pool and CMV IE1 protein were also elevated in
subjects >85 years old not infected with HIV [31]. No
HIV patients displayed symptoms of CMV disease at the
time PBMC were collected, so VLE-specific CD8 T-cells
may play a role in averting CMV replication.
Elevated CD8 T-cell IFNγ responses to VLE may re-
flect oligoclonal expansion of CMV-specific CD8 T-cells
before ART, as many patients in this study had a history
of CMV end-organ disease. Long-term ART does not in-
crease the diversity of T-cell repertoires in HIV patients
despite sustained suppression of viral replication [32].
As CMV seropositivity has been linked to “accelerated
ageing” [1], highly differentiated effector memory CD4
and CD8 T-cells were assessed by expression of CD57
and CD45RA without CD27 [12]. Proportions of CD8 T-
cells with the phenotype CD57+CD45RA+CD27− corre-
lated with age and with antibodies against the CMV IE1
protein and CD4 T cell IFNγ response to CMV lysate.
Thus demonstrates that CMV seropositivity may acceler-
ate CD8 T-cell differentiation and further worsen the
impairment caused by HIV.
HIV patients had marginally more highly differentiated
CD4 T-cells than CMV+ controls. Proportions of CD4
and CD8 T-cells from HIV patients expressing CD57
correlated with IFNγ responses to CMV antigen and
peptide (respectively), consistent with CD57+ T-cells
selectively retaining the capacity to produce IFNγ [26].
Conclusions
Overall these results establish that the immunological
“footprint" of CMV remains elevated in HIV patients
after more than 12 years on ART and correlates with
CD8 T-cell phenotypes. Elevated levels of sBAFF may be
an effect of HIV and contribute to high titres of CMV
antibody. Extension of our study in larger cohorts should
include CMV-seronegative HIV patients and CMV-DNA
assessments to further elucidate the mechanisms by
which CMV reactivation accelerates immune ageing in
HIV patients.
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Methods
Patient and control cohorts
Twenty CMV-seropositive HIV patients were selected
from the HIV database of the Department of Clinical
Immunology and Immunogenetics, Royal Perth Hospital,
Western Australia. Participants were all >50 years old
with nadir CD4 T-cell counts < 200 cells/ul, studied
after >12 years on ART and >1 year of complete viral
suppression (<50 HIV RNA copies/ml). All partici-
pants were healthy at the time of sample donation.
ART comprised at least three antiretroviral drugs in-
cluding a non-nucleoside reverse transcriptase inhibi-
tor or protease inhibitor. Sixteen CMV-seropositive
healthy controls (designated CMV+ controls) and nine
CMV-seronegative healthy controls (designated CMV-
controls) were included. Seropositivity was defined
as >1100 AU/mL of CMV lysate antibody, where the
cut-off was based on eleven samples from persons con-
firmed to be CMV seronegative by routine serology
(Abbott Diagnostic Systems, Lake Forrest, IL, USA). In-
formed consent was obtained from all participants, and
the human experimentation guidelines of Royal Perth
Hospital and University of Western Australia were
followed. Samples were screened for carriage of HLA-A*02
by flow cytometry [19]. Eleven of 20 (55 %) patients,
nine of 16 (56 %) CMV+ controls and no CMV- con-
trols, carried HLA-A*02.
T-cell subset phenotyping
Freshly collected PBMC [isolated by ficoll density gradient
centrifugation (Ficoll-Paque Plus; GE Healthcare Biosci-
ences, Sweden)] were stained for surface markers (15 min,
room temperature) using conjugated monoclonal anti-
bodies as follows: CD8-FITC (clone SK1), HLA-DR-
PE (clone TU36), CD57-APC (clone NK-1), CD45RA-
APC-H7 (clone HI100), CD27-PerCPCy5.5 (clone M-
T271), CD3-V450 (clone UCHT1) and CD4-V500
(clone RPA-TA) from BD Biosciences (San Jose, CA,
USA). Stained cells were washed twice and analysed on a
FACSCantoTM (BD Biosciences). At least 200 000 events
were acquired and analysed using FlowJo (Treestar, San
Carlos, CA, USA). Expression of CD57, CD27 and
CD45RA was used to define terminally differentiated ef-
fector memory (TEMRA) (CD57
+CD45RA+CD27−) T-cells.
For comparisons with other studies, we also identified
senescent T-cells solely by expression of CD57. Gating
strategies can be found in Additional file 1: Figure S1.
Immune activation and total IgG ELISA
Levels of sTNFR1, sCD14 (RnD Systems; Minneapolis,
MI, USA) and sBAFF (Abcam; Cambridge, UK) in plasma
were quantified using commercial reagents. Plasma was
serially diluted threefold from 1:9 for sTNFR1, 1:200 for
sCD14 and 1:3 for sBAFF enzyme linked immunosorbent
assay (ELISA). Binding of the peroxidase-conjugated sec-
ondary antibody was detected with a tetramethylbenzidine
(TMB) substrate (Sigma-Aldrich; St Louis, MI, USA). Re-
actions were stopped with 1 M sulphuric acid (H2SO4)
and quantified at 450 nm. Four-parameter logistic curves
were generated from >6 titrations of the standard using
SOFT max PRO version 5.4 software.
Total IgG was quantified using plates coated with
polyvalent goat anti-human IgG (2.5 mg/mL; Invitrogen;
Carlsbad, CA, USA) diluted 1:500 in bicarbonate buffer
and blocked with 5 % bovine serum albumin (BSA) in
phosphate buffered saline (PBS) for 60 min. Plasma sam-
ples were serially diluted threefold from 1:100,000 in 2 %
BSA/PBS and applied for 120 min. Binding was detected
using goat anti-human IgG conjugated horseradish
peroxidase (HRP) (Sigma-Aldrich) followed by TMB
substrate as described above. Hypergammaglobulinea-
mia was defined as >14 g/L IgG, as the normal range
is 6-14 mg/mL [33].
CMV-specific antibody ELISAs
IgG reactive with CMV was quantitated using CMV lysate,
CMV gB and CMV IE1. CMV lysate was prepared by son-
ication of human foreskin fibroblasts (HFF) infected with
CMV strain AD169. Uninfected HFF were prepared in par-
allel to create a control lysate. Replicate plates were coated
with CMV gB (produced in hamster ovary cells, Chiron
Diagnostics, Medfield, MA, USA; 2800–800; 50 ng/mL)
or CMV IE1 (produced in E.coli, Miltenyi Auburn,
CA; 2500 ng/mL). Plasma samples were diluted from
1:200. Bound IgG was detected as described above. A
plasma sample assigned a value of 1000 units IgG reactive
with each antigen was run on each plate, and unit values
were derived for all samples. The units calculated from
uninfected fibroblasts were subtracted from those gener-
ated using CMV-coated plates.
Detection of IFN-γ producing T-cells
ELISpot assays utilised anti-IFN-γ antibodies purchased
from MabTech (Stockholm, Sweden) and cryopreserved
PBMC with cell viability >95 % described elsewhere [26].
Cells were stimulated with anti-CD3 (10 ng/mL; Mab-
Tech), whole CMV lysate (described above), CEF control
peptide pool [contains peptides from CMV, Epstein-Barr
virus (EBV) and Influenza; 2 μg/mL; MabTech), CMV
pp65 peptide pool (NIH AIDS reagent program, DAIDS,
NIAID and Immunodiagnostics, Woburn, MA, USA),
HLA-A*02-restricted peptides NLV (residues 495–503 of
pp65) or VLE (residues 316–324 of IE-1) at 10 μg/mL
(Proteomics International, Perth, Australia). Spots >10 units
in size and >20 units in intensity were counted using an
AID ELISpot Reader System (AID, Strassberg, Germany).
Numbers of spots in unstimulated wells were subtracted
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from numbers in stimulated wells and adjusted per 2 × 106
PBMC.
Statistical analysis
Results were presented as median (range) values unless
otherwise stated. Bivariate analyses were based on Mann
Whitney tests. Correlation coefficients were determined
by the Spearman’s Rank Correlation Test (GraphPad
Prism version 5, La Jolla, CA, USA). For all tests, P < 0.05
were considered to represent a significant difference and
highlighted in bold, whereas 0.05 < P < 1 is italicized.
Additional file
Additional file 1: Figure S1. Senescent T cell gating strategy.
Lymphocytes were distinguished from monocytes by their forward and
side light scatter (a), gated for expression of CD3 (b), CD4 and CD8 (c).
Quadrant gates were then set for expression of CD45RA and CD27 within
the CD4+ (d) and CD8+ (e) populations. Gating was further set for
expression of CD57+ within the CD45RA+ CD27− CD4+ (f) and CD45RA+
CD27− CD8+ (g) populations. (PDF 261 kb)
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